Suppr超能文献

经导管主动脉瓣置换术治疗主动脉瓣感染性心内膜炎:一项系统评价及行动呼吁

Transcatheter Aortic Valve Replacement for Aortic Valve Infective Endocarditis: A Systematic Review and Call for Action.

作者信息

Brankovic Milos, Hashemi Ashkan, Ansari Julia, Sharma Abhishek

机构信息

Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.

Transatlantic Cardiovascular Study Group, Bloomfield, NJ, USA.

出版信息

Cardiol Ther. 2023 Jun;12(2):297-306. doi: 10.1007/s40119-023-00314-9. Epub 2023 Apr 20.

Abstract

We aimed to systematically analyze the literature on the use of transcatheter aortic valve replacement (TAVR) to treat active aortic valve infective endocarditis (AV-IE). Surgery is declined in one-third of patients with IE who meet indications because of prohibitive surgical risk. TAVR might be an alternative for selected patients with AV-IE as a bridge-to-surgery or stand-alone therapy. PubMed/MEDLINE, Embase, and Cochrane databases were searched (2002-2022) for studies on TAVR use in active AV-IE. Of 450 identified reports, six met inclusion criteria (all men, mean age 71 ± 12 years, median Society of Thoracic Surgeons (STS) score 27, EuroSCORE 56). All patients were prohibitive surgical risk candidates. Five out of six patients had severe, and one patient had moderate aortic regurgitation on presentation. Five out of six patients had prosthetic valve endocarditis after surgical valve replacement 13 years before (median), and one patient had TAVR a year before hospitalization. All patients had cardiogenic shock as the indication for TAVR. Four patients received balloon-expanding, and two patients received self-expanding TAVR after a median of 19 (IQR 9-25) days from diagnosis of IE. No death or myocardial infarction occurred, but one patient had a stroke within the first 30 days. The median event-free time was 9 (IQR 6-14) months including no death, reinfection, relapse IE, or valve-related rehospitalization. Our review suggests that TAVR can be considered as an adjuvant therapy to medical treatment for selected patients in whom surgery is indicated for treatment of acute heart failure due to aortic valve destruction and incompetence caused by infective endocarditis, but who have a prohibitive surgical risk. Nonetheless, a well-designed prospective registry is urgently needed to investigate the outcomes of TAVR for this off-label indication. No evidence exists for using the TAVR to treat infection-related surgical indications such as uncontrolled infection or control of septic embolization.

摘要

我们旨在系统分析有关经导管主动脉瓣置换术(TAVR)治疗活动性主动脉瓣感染性心内膜炎(AV-IE)的文献。三分之一符合手术指征的感染性心内膜炎患者因手术风险过高而拒绝手术。对于部分患有AV-IE的患者,TAVR可能作为手术过渡或独立治疗的替代方案。检索了PubMed/MEDLINE、Embase和Cochrane数据库(2002年至2022年)中有关TAVR用于活动性AV-IE的研究。在450篇已识别的报告中,6篇符合纳入标准(均为男性,平均年龄71±12岁,胸外科医师协会(STS)评分中位数为27,欧洲心脏手术风险评估系统(EuroSCORE)评分为56)。所有患者均为手术高风险候选人。6例患者中,5例初诊时有严重主动脉瓣反流,1例为中度主动脉瓣反流。6例患者中有5例在13年前(中位数)进行人工瓣膜置换术后发生人工瓣膜心内膜炎,1例患者在住院前一年接受了TAVR。所有患者均因心源性休克接受TAVR治疗。4例患者接受球囊扩张式TAVR,2例患者在诊断感染性心内膜炎后中位数为19天(四分位间距9 - 25天)接受自膨式TAVR。未发生死亡或心肌梗死,但有1例患者在术后30天内发生中风。无事件生存时间中位数为9个月(四分位间距6 - 14个月),包括无死亡、再感染、感染性心内膜炎复发或瓣膜相关再住院。我们的综述表明,对于因感染性心内膜炎导致主动脉瓣破坏和功能不全而出现急性心力衰竭且有手术高风险但又适合手术治疗的部分患者,TAVR可被视为药物治疗的辅助治疗方法。尽管如此,迫切需要一个设计良好的前瞻性注册研究来调查TAVR用于这一非适应证的疗效。目前尚无证据支持使用TAVR治疗与感染相关的手术适应证,如控制不佳的感染或感染性栓子的控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fbe/10209359/fd3089f4c771/40119_2023_314_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验